Benefits of a National Program for Adverse Drugs Reactions (ADRS) Surveillance in Diabetic Patients
Abstract
Voluntary notification of suspected adverse drug reactions (ADR) is the most worldwide method to detect these events. Unfortunately, health professionals in Latin American countries have no “culture” to notify ADR. For this reason, the National Diabetes Program (NDP) in Paraguay decided to regularly contact their patients, in order to increase ADR detection. To evaluate the results of this experience, this study was performed.
Methods: a descriptive, observational, cross-sectional study with an intervention phase was performed. A non-probabilistic sample of patients belonging to NDP was selected and compared with historical results of the program. The intervention activities consisted in a monthly contact of the patients by a member of the program.
Results: 2,390 patients with type II diabetes were enrolled in the study and compared with the same number of patients belonging to the program but with classical follow-up. Concerning the adverse drug reactions, 146 reports were registered during the study period, which mean 6.1% of all patients enrolled, while in the same period, historically the ADR reports were 0.94%. 66.9% of these reports were performed by the patients while 42.1% were notified by health professional. Main ADRs reported were vomiting 28.8%, dizziness 28.4%, diarrhea 10.8%, hypoglycemia 10.2% or abdominal pain 6.5%. The antidiabetic drugs that presented the greatest suspicion of ADRs were metformin 45.31%, glimepiride 21.8%, glibenclamide 6.25% and insulin 3.13%.
Conclusion: Periodical contact of patients covered by a National Diabetes program was able to increase 6 times the historically annual of report of pharmacovigilance adverse drug reactions.
Keywords: pharmacovigilance, adverse drug reactions, reports, voluntary, active notification, program.
Keywords:
pharmacovigilance, adverse drug reactions, reports, voluntary, active notification, programDOI
https://doi.org/10.22270/jddt.v12i4-S.5618References
PAHO. Drug Safety Surveillance. Guide for the installation and start-up of a Pharmacovigilance Center. . Uppsala, Sweeden. Published by the Uppsala Monitoring Center (the UMC). 2001. 22-26.
WHO. WHO policy perspectives on medicines. Pharmacovigilance: guarantee of safety in the use of medicines. Geneva. WHO/EDM/2004.8, 2004. P. 3-9. Available in: https://apps.who.int/iris/handle/10665/68782
Murillo MD, Fernández-Llimós F, Tuneu i Valls L. Pharmacotherapeutic follow-up guide for diabetes. Ed.: Espai Gràfic Anagrafic, S.L. Barcelona, Spain. 2019. P. 45-62. Available in: https://www.ugr.es/~cts131/esp/guias/GUIA_DIABETES.pdf
Paraguay-PAHO. National Diabetes Program. Ministry of Public Health. Paraguay Government. 2021. P. 24-35. available at: www.paho.org/spanish/ad/dpc/nc/diabetes-atlas-par.pdf.
Sweetman SC., Martindale. Pharmacotherapeutic Follow-up Guide. 3rd Edition. Barcelona. Spain. 2007. P 3515-31.
Aspinall MB, Whittle J, Aspinall SL, Maher RL, Jr, Good CB. Improving adverse-drug-reaction reporting in ambulatory care clinics at a Veterans Affairs hospital. Amer J Health Syst Pharm. 2002; 59:841–845.
Leghari Q., Chand S., Bushra R. et al. Exploration of Perception, Need and Barriers against Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Professionals’ Insight. Journal of Pharmaceutical Research International 2021; 33(7):78-86.
Published
Abstract Display: 328 
PDF Downloads: 267 PDF Downloads: 24 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.